What is the dosing range for BPC-157 + TB-500 Stack?

BPC-157 + TB-500 Stack is typically dosed at BPC-157 250mcg + TB-500 2.5mg (low), BPC-157 500mcg + TB-500 5mg (moderate), or BPC-157 750mcg + TB-500 7.5mg (high) varies by component, administered 2–3x per week. These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of BPC-157 + TB-500 Stack?

Reported side effects of BPC-157 + TB-500 Stack include: BPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history.

Healing

BPC-157 + TB-500 Stack

Also known as: Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500

Share:Share on Reddit

BPC-157 and TB-500 are research compounds. Not approved for human use.

📚 Content aggregated from:2 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models.

Research Summary

BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.

Dosing Range

low

BPC-157 250mcg + TB-500 2.5mg

moderate

BPC-157 500mcg + TB-500 5mg

high

BPC-157 750mcg + TB-500 7.5mg

Units: varies by component · Frequency: 2–3x per week

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injectionIntramuscular injection

Reconstitution Notes

Each peptide reconstituted separately. BPC-157: 5mg per 5mL bacteriostatic water (1mcg/µL). TB-500: 5mg per 2mL bacteriostatic water (2.5mcg/µL). Draw into the same syringe at time of injection only if confirmed pH compatible — some researchers prefer separate injections to ensure stability.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

BPC-157: nausea (rare), dizziness, lightheadedness
TB-500: fatigue, headache, injection site reactions
No documented combination-specific adverse effects
Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history

Research Papers

2 peer-reviewed sources

BPC-157 angiogenesis and growth factor receptor upregulation

Journal of Physiology1999

Thymosin beta-4 (TB-500 basis) actin-binding domain and tissue repair

Proceedings of the National Academy of Sciences1994

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/Peptides

Extensive community injury recovery reports with the Wolverine Stack — tendon, ligament, and muscle repair protocols.

View original thread

r/SteroidsWiki

Community protocol guides for the BPC-157 + TB-500 combination including dosing schedules and injection timing.

View original thread

Overview

The BPC-157 + TB-500 combination — colloquially called the "Wolverine Stack" in the research peptide community — has become one of the most discussed healing protocols in sports medicine and injury recovery research. The pairing is mechanistically elegant: the two compounds target completely different molecular pathways that together cover the major phases of tissue repair.

Understanding why this combination works requires understanding what each compound does independently, and where the biology of tissue healing requires both functions simultaneously.

Why These Two Compounds Are Synergistic

The Healing Cascade Requires Multiple Parallel Processes

Effective tissue repair requires:

Angiogenesis: New blood vessels to supply oxygen and nutrients to healing tissue
Growth factor signaling: VEGF, FGFR, and EGFR activation to recruit repair cells
Cell migration: Cells must physically move into the injury site
Actin cytoskeleton dynamics: Cell migration requires continuous actin polymerization/depolymerization
Anti-inflammatory regulation: Preventing excessive inflammation that impairs healing

BPC-157 primarily addresses points 1, 2, and 5. TB-500 primarily addresses points 3 and 4. Neither compound duplicates the other's function — hence the synergy.

BPC-157 in the Stack

Primary mechanisms:

Upregulates VEGFR2 expression → enhanced angiogenic response
Activates FAK-paxillin pathway → cell survival and migration signaling
Modulates nitric oxide system → vasodilation and blood flow to injury
Anti-inflammatory: inhibits COX-2, reduces NFκB-mediated inflammatory cascade
GI tract protection and healing (unique BPC-157 property — TB-500 does not have this)

TB-500 in the Stack

Primary mechanisms:

Sequesters G-actin via LKKTET domain → modulates actin polymerization dynamics
Promotes lamellipodia formation → directed cell migration toward injury
Stimulates angiogenesis via endothelial cell migration (complementary to BPC-157's receptor upregulation)
Reduces inflammatory cell infiltration and fibrosis in healing tissue
Anti-fibrotic in systemic contexts (heart, kidney research)

Comparative Mechanism Map

| Phase of Healing | BPC-157 | TB-500 | |-----------------|---------|--------| | Angiogenesis | ↑↑↑ (VEGFR2) | ↑↑ (endothelial migration) | | Inflammation control | ↑↑↑ | ↑↑ | | Cell migration | ↑ (FAK/paxillin) | ↑↑↑ (actin/lamellipodia) | | GI protection | ↑↑↑ | ↔ | | Fibrosis reduction | ↑ | ↑↑↑ | | Systemic distribution | Strong | Strong |

Reconstitution and Administration Protocol

Standard research preparation:

BPC-157 (5mg vial):

Add 5mL bacteriostatic water → 1mg/mL (1000mcg/mL)
500mcg dose = 0.5mL (50 units on U-100 syringe)

TB-500 (5mg vial):

Add 2mL bacteriostatic water → 2.5mg/mL (2500mcg/mL)
5mg dose = 2mL (some prefer 10mg vials for loading phases)

Injection timing:

2–3x/week during active injury phase
May reduce to 1–2x/week for maintenance

Loading vs. Maintenance Protocol

| Phase | Duration | BPC-157 | TB-500 | |-------|----------|---------|--------| | Loading | Weeks 1–2 | 500mcg 3x/week | 5–7.5mg 2x/week | | Maintenance | Weeks 3–12 | 250–500mcg 2x/week | 5mg 1x/week | | Washout | 4 weeks | — | — |